Designing PLS for Comprehension: Readability, Structure, Visuals, and Accessibility

Write for readers, not for authors. Determine the most important questions a person has after participating in—or considering—a study: What was the goal? Did the treatment work? What side effects occurred? How do results compare with current care? What happens next? Use short sentences, everyday words, and active voice. Avoid idioms, acronyms, and unexplained statistics. Replace “statistically significant” with “a difference unlikely to be due to chance,” and then explain what that difference means in practical terms.

Readable structure. Organize content with predictable headings: “What was the study about?”, “Who participated?”, “What treatments were compared?”, “What did researchers measure?”, “What were the main results?”, “What side effects occurred?”, “What do the results mean?”, and “Study limits.” Keep paragraphs short (3–5 sentences). Use bullets for multi-part lists (eligibility criteria, common side effects). Present numbers as absolute counts and percentages. When reporting rates, specify the time frame (for example, “over 12 months”).

Explain outcomes without jargon. Define primary and key secondary outcomes in plain terms and include the units and timing. If a composite endpoint is used, summarize its parts first, then show the composite. For diagnostic or device trials, explain accuracy measures (sensitivity, specificity) in simple language and use a brief example that avoids oversimplification.

Visuals that inform, not persuade. Use simple charts to show the direction and size of differences. Prefer bar or line charts without 3D effects. Label axes plainly and include captions that interpret the pattern (“People taking Treatment A reported fewer headaches than those on Treatment B”). Provide alt text for every image and ensure charts are readable in grayscale for printing.

Accessibility and inclusion. Make PLS accessible to screen readers (semantic headings, alt text, table headers). Avoid color-only distinctions. Use high-contrast palettes by default. Offer downloadable text or audio where feasible. Provide translations where the study recruited multilingual populations; ensure key medical terms are checked by native speakers for clarity. For pediatric-focused summaries, address caregivers directly and explain unfamiliar procedures with everyday analogies.

Balance and tone. Communicate uncertainty and study limitations plainly: small sample sizes, short follow-up, missing data, or protocol deviations that could affect interpretation. Avoid superlatives, branding, or promotional language. If results are negative or mixed, say so clearly and explain what researchers learned and what future studies may explore.

Privacy and dignity. Reassure readers that individual identities are protected and that only combined results are shown. If photos or quotes are used (rare), obtain documented consent and avoid any information that could identify a participant.

Operating Model: Roles, Workflows, Version Control, and Alignment with Public Results

Decision rights and reviewers. A lean governance model prevents drift. Typical roles: the Record Owner (Transparency or Regulatory) builds the draft; Clinical/Statistics verifies numbers and interpretations; Medical Writing ensures readability and plain language; Patient Engagement or an advisory panel tests comprehension; Legal/Privacy confirms de-identification and redaction boundaries; and Quality checks ALCOA++ attributes—attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available.

Inputs and single source of truth. Your PLS should draw numbers from the same tables that feed the public results record and the clinical study report. Lock an “evidence pack” for each summary: finalized tables, a cross-walk of terms (technical → lay), a style sheet (units, rounding rules), and screenshots/exports of the posted results with timestamps. Require sign-offs that capture the meaning of each signature (“Statistical accuracy approval,” “Readability approval,” “Privacy approval”).

Timelines and dependencies. Work backward from the earliest external deadline. Set internal milestones for content freeze, patient-panel review, translation, legal/privacy review, and publication. Build a buffer for one quality-control (QC) cycle—registries routinely return submissions for clarification. Align your lay summary with the public results record so readers encounter the same outcomes, denominators, and dates.

Localization and translation. Start with a master English version and an approved glossary of high-risk terms (procedures, risks, units). Translate into target languages and back-check with native reviewers. Maintain a short country annex when law or convention requires specific phrasing; otherwise keep one global message. Track version numbers and languages on the title page, and store translator attestations alongside signatures.

Decentralized trial specifics. If the study used eConsent, tele-visits, home-health procedures, or wearable sensors, mention these in the “How the study was conducted” section. Keep explanations concise and clear (“Some visits took place by secure video call”). Avoid technical details that do not change interpretation.

Redaction and confidentiality. Remove or mask commercially confidential information where rules allow or require, but keep the story coherent. Avoid empty sections that invite confusion. If certain details are deferred under applicable policies, say so briefly (“Some information will be published later to protect ongoing research”), and ensure the lay narrative still explains the results.

Evidence of accessibility. Retain readability scores, patient-panel feedback notes, and before/after edits. Store alt text and language files with timestamps. During audits, be prepared to show that accessibility and inclusivity were designed in—not added at the end.

Quality, Metrics, Risks, and a Ready-to-Use Checklist

Quality rules that prevent findings. Use measurable outcomes with units and time frames. Present absolute numbers and percentages, keeping denominators consistent. Explain missing data and major protocol deviations simply and fairly. Use the same treatment and arm names everywhere. Include a short, plain-language limitations section. Add a “What the results mean” paragraph that connects outcomes to everyday decisions without making treatment claims or recommendations.

Metrics that predict control (KPIs/KRIs).

• Timeliness: median days from database lock to PLS content freeze; median days from freeze to publication; percentage of summaries published by the applicable deadline.
• Quality: percentage passing first QC without major returns; readability scores within target range; consistency defects (PLS vs. posted results) per submission.
• Accessibility & inclusion: percentage with complete alt text; number of languages released at first posting; patient-panel comprehension pass rate.
• Effectiveness: recurrence rate of the same QC defect category; time-to-green for sites or vendors that miss language or accessibility standards.

Common pitfalls—and durable fixes.

• Over-technical writing. Fix with a mandatory plain-language cross-walk and patient-panel review before sign-off.
• Number mismatches. Lock a single evidence pack for PLS, public results, and publications; require statistician sign-off on final numbers.
• Missing accessibility features. Build alt text and semantic headings into templates; run an automated accessibility check as part of QC.
• Opaque redactions. Where details are deferred, provide a one-sentence explanation and keep the narrative coherent.
• Fragmented ownership. Centralize accountability with a named Record Owner and require signatures that state their meaning.

30–60–90 day rollout plan.

• Days 1–30: publish SOPs and style guide; create master templates (structure, charts, alt text, translator notes); assemble patient advisors; build the evidence-pack checklist.
• Days 31–60: pilot two completed studies; track timelines and QC outcomes; refine glossary and accessibility checks; align with public results workflows.
• Days 61–90: scale across programs; set monthly metrics; add vendor requirements (turnaround time, audit trails); run a retrieval drill (show PLS → evidence pack → posted results) within minutes.

Ready-to-use checklist (paste into your SOP).

• Purpose, design, participants, interventions, outcomes, safety, results, and limitations covered in plain language.
• Numbers match public results tables; denominators and time frames consistent; composite endpoints explained.
• Readability in target range; jargon removed; terms defined once.
• Charts labeled simply; alt text written; color not the only cue.
• Translations completed and back-checked; language and version displayed; translator attestations stored.
• Redaction applied where permitted; narrative remains coherent; one-sentence deferral note if applicable.
• Sign-offs captured with meaning of signature; evidence pack filed (tables, cross-walk, screenshots with timestamps).
• Patient-panel comprehension verified; edits recorded; accessibility test passed.
• Publication date aligned to earliest external deadline; monitoring set for future updates or long-term follow-up.
• TMF/ISF filing locations mapped; retrieval drill passed in under five minutes.

Bottom line. Plain-language summaries succeed when they are written for people, backed by a single source of truth, reviewed by experts and patients, accessible across languages and abilities, and aligned with public results. A disciplined operating model—anchored in international guidance from ICH, FDA, EMA, WHO, PMDA, and TGA—turns disclosure from a last-minute scramble into a reliable, respectful system that participants and regulators can trust.